Homologous recombination deficiency signature (HRDsig) status in <i>BRCA1/2</i> wild type ( <i>BRCA1/2</i> wt) clinically advanced prostate cancer (CAPC).
Georges Gebrael(University of Utah), Neeraj Agarwal(University of Utah), Alina Basnet(Cancer Clinic), A. Kamat(The University of Texas MD Anderson Cancer Center), R. Graf(Foundation Medicine (United States)), Douglas I. Lin(Foundation Medicine (United States)), Ole Gjoerup(Foundation Medicine (United States)), S. Gupta(Cleveland Clinic), Sumanta Kumar Pal(City Of Hope National Medical Center), Gennady Bratslavsky(SUNY Upstate Medical University), J L Lortat Jacob(SUNY Upstate Medical University), Andrea Necchi(Vita-Salute San Raffaele University), Petros Grivas(University of Washington), Philippe E. Spiess(Moffitt Cancer Center), Jeffrey S. Ross(SUNY Upstate Medical University), Dean C. Pavlick(Foundation Medicine (United States)), Liang Cheng(Brown University), Hanan Goldberg(SUNY Upstate Medical University), R. Li(Moffitt Cancer Center)
Cited by 0
Related Papers
Sporadic renal angiomyolipoma in a patient with Birt-Hogg-Dubé: chaperones in pathogenesis
|Oncotarget|2018|15
Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.
|Journal of Clinical Oncology|2024|9
Adjuvant Atezolizumab in Patients with Sarcomatoid Renal Cell Carcinoma: A Prespecified Subgroup Analysis of IMmotion010
|European Urology Oncology|2024|4
Zanzalintinib (XL092) plus nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study.
|Journal of Clinical Oncology|2024|1